Spirax-Sarco Engineering plc

Spirax reported first-half organic sales growth of 5%, organic profit growth of 6%, adjusted operating margin of 19.8% (+10 bps organically), and adjusted EPS up 9% to 150p. By segment, STS sales grew 1% with margin at 22% (-170 bps), ETS sales grew 11% with margin at 17.2% (+220 bps), and Watson-Marlow sales grew 7% with margin at 27.5% (+80 bps). Adjusted cash from operations was GBP 92 million, cash conversion was 54%, net debt was GBP 618 million, and net debt-to-EBITDA was 1.6x. Management reiterated full-year guidance, expects higher sales volumes in the second half, full-year cash conversion around 90%, CapEx at the lower end of 4% to 5% of sales, FX to be a negligible full-year revenue impact and a 2% profit headwind in H2, and STS full-year margin to be broadly in line with last year while ETS and Watson-Marlow improve.

Nimesh Patel framed the quarter as proof that the Together for Growth strategy is embedding Spirax’s ability to grow ahead of its markets despite weak industrial production. He emphasized diversification, self-generated demand, and investments in sales capability, digital connectivity, and decarbonization as the reasons Spirax can keep outperforming IP. His tone was confident and constructive, especially on the medium-term outlook, China inflection, and the durability of growth in ETS and Watson-Marlow.

Louisa Burdett highlighted that the first half was in line with expectations and supported by growth across all three businesses. She cited adjusted operating margin of 19.8%, adjusted EPS of 150p, cash from operations of GBP 92 million, cash conversion of 54%, net debt of GBP 618 million, and leverage of 1.6x, which she said should move back inside the 1 to 1.5x target range by year-end. She also noted GBP 5 million of restructuring cash outlay, CapEx around 3% of sales, expected full-year CapEx at the low end of 4% to 5% of sales, and a 50.4p interim dividend up 3%.

Analysts focused on STS demand momentum, China, ETS margin sustainability, semiconductor growth, Watson-Marlow’s runway, and capital allocation. Management said STS saw greater than 2x IP demand growth, that China’s inflection could come earlier than previously expected, and that the H2 margin recovery should benefit from higher shipments and no further major reinvestment. On ETS, they said the 20% target remains achievable, pricing is only a later-cycle upside, and the business can exceed 20% but may choose to reinvest for growth. On capital allocation, management reiterated bolt-on M&A as a priority and said buybacks would only be considered if leverage reaches the bottom of the 1 to 1.5x range and attractive reinvestment opportunities are lacking.